Seborrhea - Pipeline Review, H1 2017

  • ID: 4115122
  • Report
  • 39 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Amorepacific Corp
  • EpiPharm AG
  • Phosphagenics Ltd
  • Vyome Biosciences Pvt Ltd
  • MORE
Seborrhea - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Seborrhea - Pipeline Review, H1 2017, provides an overview of the Seborrhea (Dermatology) pipeline landscape.

Seborrhea is form of skin eczema that mainly affects scalp, ears, face, chest, and folds of skin. Symptoms include skin flakes, red skin, itching and skin lesions. Risk factors include stress or fatigue, skin acne and obesity. Treatment includes antifungal medications.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Seborrhea - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Seborrhea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Seborrhea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 2, 2 and 2 respectively.

Seborrhea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Seborrhea (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Seborrhea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Seborrhea (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Seborrhea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Seborrhea (Dermatology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Seborrhea (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Seborrhea (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aclaris Therapeutics Inc
  • Amorepacific Corp
  • EpiPharm AG
  • Phosphagenics Ltd
  • Vyome Biosciences Pvt Ltd
  • MORE
Introduction

Seborrhea - Overview

Seborrhea - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Seborrhea - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Seborrhea - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Amorepacific Corp

Biomar Microbial Technologies

EpiPharm AG

Phosphagenics Ltd

Vyome Biosciences Pvt Ltd

Seborrhea - Drug Profiles

artemether - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

hydrogen peroxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-07A081 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IB-07A085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Seborrhea - Dormant Projects

Seborrhea - Discontinued Products

Seborrhea - Product Development Milestones

Featured News & Press Releases

Feb 27, 2017: Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis - a Common Skin Condition

Nov 15, 2016: Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition

Oct 19, 2016: New Observational Study Demonstrates Patient Impact of Seborrheic Keratosis, A Common, Undertreated Skin Condition Affecting 83.8 Million Americans

Jul 25, 2016: Aclaris Therapeutics Completes Enrollment of Phase 3 Pivotal Trials of A-101 for the Treatment of Seborrheic Keratosis; Provides Update on Clinical Programs

Jan 19, 2016: Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis

Mar 17, 2015: Aclaris Therapeutics’ Lead Drug Candidate A-101 Achieves Statistically Significant Results in Third Phase 2 Clinical Trial for Seborrheic Keratosis, a Common Type of Benign Skin Tumor

Jan 27, 2015: Aclaris Therapeutics Announces Positive Results from Phase 2b Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Benign Skin Tumor

Jun 30, 2014: Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Seborrhea, H1

Number of Products under Development by Companies, H1

Products under Development by Companies, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Seborrhea - Pipeline by Aclaris Therapeutics Inc, H1

Seborrhea - Pipeline by Amorepacific Corp, H1

Seborrhea - Pipeline by Biomar Microbial Technologies, H1

Seborrhea - Pipeline by EpiPharm AG, H1

Seborrhea - Pipeline by Phosphagenics Ltd, H1

Seborrhea - Pipeline by Vyome Biosciences Pvt Ltd, H1

Seborrhea - Dormant Projects, H1

Seborrhea - Discontinued Products, H1

List of Figures:

Number of Products under Development for Seborrhea, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aclaris Therapeutics Inc
  • Amorepacific Corp
  • Biomar Microbial Technologies
  • EpiPharm AG
  • Phosphagenics Ltd
  • Vyome Biosciences Pvt Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll